On May 2, 2007 – Nucleonics received FDA approval for its phase I human clinical trials for an investigational “eiRNA” therapy (NUC B1000), an “expressed interfering RNA”-based antiviral, for chronic hepatitis B. According to Nucleonics, “Proteins and enzymes are essential such that many, if not all, diseases are accompanied by abnormal gene function that results in either abnormal proteins being made or normal proteins being made either in the wrong cell or at the wrong time.Many diseases could be treated or cured by finding a way to eliminate a specific abnormal RNA molecule made within the diseased or infected cell.” Its eiRNA therapy offers a unique opportunity to address unmet clinical needs for HBV: effectiveness against all HBV genotypes and viral escape mutants because of its multi-target design; down-regulation of multiple HBV antigens as well as inhibition of viral replication; and compatibility with existing HBV therapies. For more information, visit www.nucleonicsinc.com.